Palisade Bio Inc (NASDAQ: PALI) announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN), highlighting LB1148 reduced incidence of adhesions by 72% in patients undergoing bowel resection.

• Studies assessed the efficacy of LB1148 to reduce the formation of adhesions in subjects undergoing abdominal surgery.

• Pooled data exhibited that LB1148 reduced the extent and severity of adhesions by 93% in patients undergoing bowel resection.

• The incidence of adhesions in the placebo group was similar to the published incidence (89% and ≥90%, respectively).

• Related: Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions.

• 100% of placebo-treated subjects underwent a laparoscopic procedure, and 8 of 9 had ≥ 1 adhesions.

• 75% of the 8 LB1148-treated subjects underwent a laparoscopic procedure, and 2 of 6 had ≥ 1 adhesions.

• No drug-related serious adverse events occurred in the trials.

• A total of 3/11 subjects in LBS-IST-POI-101 and 14/120 subjects in LBS-POI-201-CN underwent a second surgery.

• Price Action: PALI shares are down 14.40% at $1.01 during the market session on the last check Wednesday.

See more from Benzinga

• Protagonist Therapeutics Earns M Milestone Payment From Janssen Biotech

• FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.